SCHEMBL6239797

SCHEMBL6239797

CC(C)CCn1c(=O)c(C2=NS(=O)(=O)c3ccccc3N2)c(O)c2cc(NC(=O)c3cccc(F)c3)ccc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.59
NR1I2 O75469 1/20 0.59
MAPK1 P28482 1/20 0.54
HSD17B10 Q99714 1/20 0.54
XBP1 P17861 1/20 0.41
RAB9A P51151 5/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
NPC1 O15118 4/20 0.35
CNR2 P34972 1/20 0.35
DYRK3 O43781 1/20 0.35
ROCK2 O75116 1/20 0.35
MAP4K4 O95819 1/20 0.35
RPS6KB1 P23443 1/20 0.35
CLK2 P49760 1/20 0.35
CSNK2A1 P68400 1/20 0.35
ROCK1 Q13464 1/20 0.35
DYRK1A Q13627 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6267540 0.93 CYP2C9 (0.61) CYP2C9NR1I2MAPK1HSD17B10XBP1
SCHEMBL6231895 0.93 MAPK1 (0.58) CYP2C9NR1I2MAPK1HSD17B10ALDH1A1
SCHEMBL6242212 0.90 MAPK1 (0.53) CYP2C9NR1I2MAPK1HSD17B10RAB9A
SCHEMBL6241366 0.89 MAPK1 (0.54) CYP2C9NR1I2MAPK1HSD17B10RAB9A
SCHEMBL6234807 0.87 MAPK1 (0.61) CYP2C9NR1I2MAPK1HSD17B10ALDH1A1
SCHEMBL6239211 0.87 MAPK1 (0.54) CYP2C9NR1I2MAPK1HSD17B10RAB9A
SCHEMBL6235380 0.87 CYP2C9 (0.55) CYP2C9NR1I2MAPK1HSD17B10XBP1
SCHEMBL6738143 0.86 CYP2C9 (0.74) CYP2C9NR1I2MAPK1HSD17B10XBP1
SCHEMBL6234425 0.86 MAPK1 (0.53) CYP2C9NR1I2MAPK1HSD17B10RAB9A
SCHEMBL6230351 0.86 MAPK1 (0.59) CYP2C9NR1I2MAPK1HSD17B10RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP claimed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 CYP2C9 1218/4885NR1I2 1798/4885MAPK1 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.